Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluating dirucotide

(MBP8298) for the treatment of SPMS. Enrollment for the randomized,

double-blind study was initiated in June, 2007 and to date there have

been in excess of 375 patients enrolled. The trial will include

approximately 510 patients at approximately 68 sites across the U.S.

To date, the DSMB has conducted two reviews of the data from this

trial and has recommended it continue. The trial is expected to

complete enrollment in mid-2008.

- MINDSET-01: A phase II clinical trial evaluating dirucotide (MBP8298)

for the treatment of relapsing-remitting MS (RRMS). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in 6 countries across Europe. The DSMB has

completed three safety analyses to date and recommended that the

trial continue as per the protocol. Completion of the trial is

expected at the end of 2008 with results anticipated in the first

half of 2009.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298). Under the terms of the agreement, Lilly and BioMS will collaborate on the development of dirucotide (MBP8298) and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US $410
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... FamilyFarms Group is pleased to announce ... Line Farms, received the 2015 Tomorrow’s Top Producer Horizon ... age of 35, who has demonstrated excellence in the ... win the Tomorrow's Top Producer Horizon Award. Every year ... Producer Award and learning from their experiences. It is ...
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... February 26, 2015 The Movement for ... to support life extension technologies and awareness. The event ... Coordinated Time, on March 21st 2015, in a live ... , Eric Schulke, Founder of MILE, says, “Our lives ... urgency. The Movement for Indefinite Life Extension is raising ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... ... and stone how-to. , ... GA (PRWEB) September 16, 2009 - Tile Media Properties (TMP), best known for The Tile ... and tile machines. The 10 year-old Atlanta-based company receives millions of unique visitors annually and ...
... , PHILADELPHIA, Sept. 16 BioNanomatrix, Inc., a ... and personalized medicine, today announced that Dr. Charles Lee and ... Dr. Lee is a pioneer in the field of ... Medical School and the Broad Institute. Dr. Barker, the ...
... , , ... today announced that it completed the initial closing of ... will be used primarily to support the company,s ongoing ... designed to reestablish healthy vasculature following common interventions to ...
Cached Biology Technology:The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... each other using chemicals called neurotransmitters. One of those ... shows up in unusually high amounts in some aggressive ... School of Medicine in St. Louis. , The researchers ... lung, thyroid, and prostate cancers that spread to other ...
... analysis of ancient DNA, a team of researchers has obtained ... shared by the large predatory cats that once roamed the ... August 9 issue of Current Biology by Ross Barnett of ... Britain, the United States, Sweden, and Australia. , Toward the ...
... findings with implications for pandemic influenza, a new study reports ... influenza virus can spread from poultry to humans. The ... of Infectious Diseases, now available online. , Crossing the species ... flu virus with pandemic potential. Previous studies have focused on ...
Cached Biology News:Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 3DNA traces evolution of extinct sabertooths and the American cheetah-like cat 2European Commission funds EBI to do new research on synergies between bioinformatics and medical informatics 2
... The IDS Corticosterone kit is a ... of corticosterone in mouse or rat serum ... not sole, corticosteroid in rats and mice, ... amphibia, birds and reptiles. Most mammals produce ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
... for all tested applications). ... from within residues 1 - 100 of Mouse ... proprietary) (Peptide available as ... 5453 Swiss Protein ID: ...
Biology Products: